TRIM32 and breast carcinoma: One study examined TRIM32, a member of the tripartite motif (TRIM) family of proteins, overexpressed in human breast cancers and mediates cisplatin resistance through activation of the NF-κB signaling pathway; subsequently, it was found that inhibition of the NF-κB pathway decreased the effects of TRIM32 and ultimately downregulated cell viability [21].